Introduction {#Sec1}
============

The number of percutaneous coronary interventions (PCIs) has increased worldwide \[[@CR1]\], as PCIs are widely accepted as a safe treatment option for stable angina and acute coronary syndrome (ACS) \[[@CR2], [@CR3]\]. This increase is caused in part by demographic reasons (ageing population) and lifestyle choices increasing cardiovascular risk \[[@CR4]\]. The need for urgent cardiac surgery due to complications of PCIs has decreased since the introduction of coronary stents, better techniques, and improved antiplatelet drugs \[[@CR2], [@CR3], [@CR5]--[@CR7]\].

To meet the increase in need for PCIs, it was proposed to start PCIs at hospitals that do not have on-site facilities for cardiac surgery back-up, so-called off-site PCIs. Initially, the American cardiac societies advised against off-site (non-primary) PCIs \[[@CR8], [@CR9]\], but this was adjusted after numerous studies showed it to be safe \[[@CR10]--[@CR18]\]. In the Dutch and British Guidelines off-site PCIs have been accepted for some time now \[[@CR19], [@CR20]\]. However, off-site centres do require high operator and institutional volumes, as well as a proven, tested plan for rapid transport to a nearby hospital with cardiac surgical capability \[[@CR18]--[@CR20]\]. A good collaboration with cardiac surgeons, with regular heart team meetings between cardiac surgeons and cardiologists is another key factor for success of off-site PCI \[[@CR12]\]. Despite this, there are also contradicting results showing off-site PCIs to have a higher mortality \[[@CR21]\].

The delay in the treatment of ST-segment elevation myocardial infarction (STEMI) patients should be 90 min or less \[[@CR22], [@CR23]\]. This should be achieved in the Netherlands in 90 % of the STEMI patients \[[@CR24]\]. In the Venlo area, this goal is only reached in about 60 % \[[@CR25]\].

Off-site PCI started in the Netherlands in 2003. The Medical Centre Alkmaar (MCA) was designated by the Dutch Government as a trial off-site PCI centre \[[@CR12]\]. After the success of this PCI centre, 14 other Dutch hospitals started performing off-site PCIs. VieCuri Medical Centre for Northern Limburg in Venlo started off-site PCIs in 2011, firstly driven to shorten the delay in treatment of STEMI patients \[[@CR26]\].

In this article we report the first results of off-site PCI and fractional flow reserve (FFR) measurement at our institution.

Methods {#Sec2}
=======

This is a retrospective cohort study from the start of PCIs at VieCuri Venlo in September 2011 until July 2012.

All patients scheduled for a PCI and/or FFR procedure at VieCuri Venlo were included. Patients undergoing FFR measurements were also included, as the complications of these patients can be similar \[[@CR4], [@CR27], [@CR28]\]. No patients were excluded after scheduling. The data of our study were, if possible, compared with data from MCA \[[@CR12]\].

PCI and FFR procedures {#Sec3}
----------------------

Patients were scheduled for a PCI and/or FFR procedure in Venlo if they had ischaemic coronary artery disease. Ischaemic coronary artery disease was defined as angina with proven myocardial ischaemia or ACS. All indications were discussed and agreed on by the Heart Team, led by an interventional cardiologist and a cardiothoracic surgeon, from Maastricht University Medical Centre (MUMC), by using an advanced webviewer (Evocs®, Fysicon, the Netherlands). Emergency (surgical) back-up was also arranged via MUMC.

Patients did not undergo the procedure in Venlo if they were eligible for PCI but classified as 'high risk'. These patients were sent to a tertiary hospital and were (mostly) patients with unprotected left main artery vessel disease or 3-vessel coronary disease. In our first year most patients in need of primary PCI were sent to Catharina Hospital Eindhoven (CZE). No patients were sent for rescue PCI, as thrombolysis is no longer a treatment option for ACS in the Netherlands.

The choice for drug-eluting or bare-metal stent, intravascular ultrasound and intra-aortic balloon pump was left to the discretion of the interventional cardiologist. Rotablation was not available in our hospital.

During the procedure, patients were given intravenous heparin. All patients were treated with double antiplatelet therapy.

Data and outcome measures {#Sec4}
-------------------------

Baseline characteristics, PCI and FFR characteristics and complications were retrospectively found in medical records. Lesion types are given according to the guidelines \[[@CR29]\].

The primary endpoint of this study was major adverse cardiovascular events (MACE) at 6 months, a combined endpoint of mortality, myocardial infarction (MI) and/or revascularisation. The secondary endpoint was major adverse cardiovascular and cerebral events (MACCE) at 6 months, including (non-)cardiac mortality, (non-)target vessel MI, target, non-target or FFR vessel re-PCI, emergency or semi-elective coronary artery bypass graft (CABG), and ischaemic or haemorrhagic cerebrovascular accident, major or minor bleeding described by the thrombolysis in myocardial infarction bleeding criteria (TIMI) \[[@CR30]\] and the need for blood transfusion. Follow-up was found in medical records or acquired through the general practitioner.

Only elective PCIs were compared between Venlo and Alkmaar as the study from Alkmaar included patients who underwent PCI (and not FFR measurement), and our study primarily consisted of elective PCIs. As Alkmaar only started elective PCIs in their second year, our first-year results are compared with their second-year results. The endpoints are compared at 30-day follow-up.

Data analysis {#Sec5}
-------------

Data were collected and analysed by an independent investigator in SPSS version 19. Frequencies, means and medians were calculated and the χ^2^ or Fisher's exact test was used to compare the results of the two hospitals. A *p*-value of \<0.05 was considered to be statistically significant.

Results {#Sec6}
=======

A total of 333 patients underwent a PCI and/or FFR procedure in the study period at VieCuri. In these patients 330 lesions were treated with PCI and 143 lesions were evaluated with FFR. No patients were excluded.

Characteristics {#Sec7}
---------------

Baseline characteristics including risk factors and comorbidities are summed up in Table [1](#Tab1){ref-type="table"}. All characteristics were normally distributed among the PCI and FFR groups. A P2Y~12~ inhibitor was prescribed in 94.0 % of the patients. In the group of patients who underwent a PCI, a P2Y~12~ inhibitor was prescribed in 100 % of the patients before the procedure.Table 1Baseline characteristics and prescribed medicationCharacteristics  Mean age, years (SD)65.1 (11.4)  Male gender, n (%)243 (73.0 %)  Diabetes, n (%)72 (21.6 %)  Hypertension, n (%)161 (48.5 %)  Hypercholesterolaemia, n (%)163 (49.1 %)  Smoker, n (%)122 (40.7 %)  Family history of CAD, n (%)146 (43.8 %)  Peripheral vessel disease, n (%)31 (9.3 %)  Previous MI, n (%)93(27.9 %)  Previous PCI, n (%)107 (32.1 %)  Previous CABG, n (%)27 (8.1 %)  Previous stroke/TIA, n (%)41 (12.3 %)  Renal disease, n (%)21 (6.3 %)  Metastatic cancer, n (%)4 (1.2 %)  LVEF \<0.40, n (%)20 (6.7 %)  LVEF, mean (SD)58.75 (11.0)Medication  Aspirin, n (%)313 (94.0 %)  Vitamin K antagonist, n (%)33 (9.9 %)  P2Y~12~ inhibitor, n (%)313 (94.0 %)  ACE inhibitor, n (%)110 (33.0 %)  Angiotensin-II-inhibitor, n (%)82 (24.6 %)  Beta blocker, n (%)288 (86.5 %)  Statin, n (%)310 (93.1 %)  Nitrate, n (%)201 (60.4 %)  Calcium antagonist, n (%)105 (31.5 %)  Alpha-1-inhibitor, n (%)10 (3.0 %)  Diuretics, n (%)84 (25.2 %)*CAD* coronary artery disease, *TIA* transient ischaemic attack, *LVEF* left ventricular ejection fraction, *ACE* angiotensin-converting-enzyme

Angiographic characteristics {#Sec8}
----------------------------

Of the 257 PCIs, 23 were primary PCIs. Overall, the procedures were successful in 94.9 % of the patients. Multi-vessel PCI was performed in 26 patients. The patients with 4 lesions all had at least one FFR measurement.

The procedure was unsuccessful in 20 cases. This was mostly due to failure to cross the lesion with a wire or the need for rotablation. Causes for the inability to pass a wire across the lesions were small vessels, extensive calcifications or ≥90˚ bends in the vessels. Lesion types were as followed: type A 25.2 %, type B1 20.1 %, type B2 31.1 % and type C 23.7 %.

Further angiographic characteristics are mentioned in Table [2](#Tab2){ref-type="table"}.Table 2Technical PCI and FFR specifications and angiographic detailsSpecifications  Total sites473  Primary PCI, n (%)23 (6.9 %)  Stents/PCI1.35  Stents/target lesion1.05  Average stent length, mm16.7  Final stent diameter, mm3.19  DES stent, (%)300 (86.7 %)  Unsuccessful, n (%)17 (5.1 %)Vessel  LM, n (%)10 (2.1 %)  LAD, n (%)227 (48.0 %)  RCX, n (%)98 (20.7 %)  RCA, n (%)141 (29.8 %)  Graft, n (%)7 (1.5 %)Vessel disease  On vessel, n (%)263 (79.0 %)  Two vessels, n (%)61 (18.3 %)  Three vessels, n (%)9 (2.7 %)Lesions  1, n (%)229 (68.8 %)  2, n (%)72 (21.6 %)  3, n (%)28 (8.4 %)  4, n (%)4 (1.2 %)Diameter lesion  Not significant, n (%)13 (2.8 %)  \<50 %, n (%)26 (5.5 %)  50 %, n (%)44 (9.3 %)  50--70 %, n (%)92 (19.5 %)  70--90 %, n (%)121 (25.6 %)  90--99 %, n (%)157 (33.2 %)  100 %, n (%)20 (4.2 %)*PCI* percutaneous coronary intervention, *DES* drug-eluting stent, *LM* left main coronary artery, *LAD* left anterior descending coronary artery, *RCX* ramus circumflex coronary artery, *RCA* right coronary artery

Procedural complications {#Sec9}
------------------------

In total, 19 (5.7 %) patients had a procedural complication.

In three patients PCI was complicated by no-reflow. The first patient had a PCI of a venous graft and suffered an inferior MI due to no-reflow. No embolic protection device was used, as it was judged not necessary in this patient. In the other two patients, no-reflow in native vessels during PCI was accepted and treated conservatively. One of these patients suffered from a non-STEMI, the other had a minimal isolated rise in troponin.

No patients died due to a complication of the procedure or required cardiac surgery as a result of the procedure. One patient did, however, require surgery at the arterial access site due to excessive bleeding. The median fluoroscopy time was 7.13 min This was longer during PCIs then during FFR procedures (7.27 vs. 4.26 min) and the longest in patients who required both FFR measurement and PCI (10.41 min).

There were 32 (9.6 %) patients with minimal bleeding. This was not defined as a complication. In Table [3](#Tab3){ref-type="table"} an account of the complications in the study population is given.Table 3Procedural complications of PCI and/or FFRComplicationsTotal, n (%)19 (5.7 %)Unsuccessful with complication, n (%)5 (1.5 %)Acute vessel closure, n (%)2 (0.6 %)Coronary dissection, n (%)9 (2.7 %)Femoral/radial dissection, n (%)1 (0.3 %)Stent thrombosis, n (%)1 (0.3 %)No-reflow, n (%)3 (0.9 %)MI, n (%)2 (0.6 %)Coronary perforation, n (%)0 (0.0 %)Cardiac tamponade, n (%)0 (0.0 %)Haemodynamic instability, n (%)1 (0.3 %)CVA, n(%)0 (0.0 %)TIMI major bleeding, n (%)1 (0.3 %)TIMI minor bleeding, n (%)4 (1.2 %)Transfusion, n (%)1 (0.3 %)Need for cardiac surgery, n (%)0 (0.0 %)Death, n (%)0 (0.0 %)Fluoroscopy time, median min (SD)7.13 (9.5)*MI* myocardial infarction, *CVA* cerebrovascular accident, *TIMI* thrombolysis in myocardial infarction, Bleeding as described by the TIMI bleeding criteria

Follow-up at 6 months {#Sec10}
---------------------

At the 6-month follow-up a MACE occurred in 43 (13.1 %) patients. In the follow-up period of 6 months, seven patients died. None of the deaths were related to the PCI or FFR procedures.

Among the seven deaths, there were three non-cardiac deaths. One patient died of severe chronic obstructive pulmonary disease. The second patient died of cerebral haemorrhage (using double antiplatetet therapy) and the third patient died of hypoxic respiratory failure due to pneumonia. The other four patients had cardiac-related deaths. In two patients, admitted with severe haemodynamic instability due to acute MI, primary PCIs were performed in our hospital as transportation to CZE was judged impossible. Neither of these patients had had a PCI before this event. One of these patients suffered from a massive subacute anterior wall MI. Despite thrombosuction and stent placement during PCI, the flow was not restored. The patient developed pneumonia and died 2 days later. The other patient suffered from an inferior MI with expansion to the right ventricle. Coronary flow was restored during PCI. However, the patient had pulseless electrical activity on the intensive care unit during hypothermia treatment despite pacing and medication. The third cardiac-related death was a patient who died due to a posterior wall rupture during weaning from the heart-lung machine after mitral valve surgery for endocarditis. The former PCI was a work-up before surgery. The last patient, with an extensive history including pulmonary disease and a recently operated rectal carcinoma, died after resuscitation for sudden bradycardia followed by asystole. This happened 4 months after bare-metal stent implantation for diffuse stenosis of the right coronary artery. The family did not consent to autopsy.

All bleeding during follow-up was of gastrointestinal origin (Table [4](#Tab4){ref-type="table"}).Table 4Six-month follow-upEndpointMACE, n (%)43 (13.1 %)Death total, n (%)7 (2.1 %)Cardiac death, n (%)4 (1.2 %)Non-cardiac death, n (%)3 (0.9 %)MI total, n(%)5 (1.5 %)Target vessel MI, n (%)3 (0.9 %)Non-target vessel MI, n (%)2 (0.6 %)Re-PCI total, n (%)32 (9.8 %)Target vessel PCI, n (%)13 (4.0 %)Non-target vessel PCI, n (%)14 (4.3 %)PCI of FFR lesion, n(%)7 (2.1 %)CABG total, n (%)11 (3.4 %)Emergency CABG, n (%)3 (0.9 %)Semi-elective CABG, n (%)8 (2.4 %)CVA total, n (%)9 (2.7 %)Ischaemic CVA, n (%)7 (2.1 %)Haemorrhagic CVA, n (%)2 (0.6 %)Major bleeding, n (%)1 (0.3 %)Minor bleeding, n (%)2 (0.6 %)Transfusion, n (%)2 (0.6 %)*MACE* major adverse cardiac events, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, Bleeding as described by the TIMI bleeding criteria

Characteristics and follow-up compared with MCA {#Sec11}
-----------------------------------------------

When comparing the populations from Venlo and Alkmaar, most characteristics and specifications did not differ significantly. However, the Alkmaar population had significantly more patients with two lesions and significantly less patients with one lesion (Table [5](#Tab5){ref-type="table"}).Table 5Comparison Venlo and AlkmaarCharacteristicsVenloAlkmaarPTotal PCI, n257781Elective PCI, n237483PCI target lesions3301020Men, n (%)188 (73.2 %)545 (70 %)NSMean age, years (SD)65.0 (11.6)64.5Stents/PCI1.351.2Stents/target lesion1.050.91Average stent length, mm16.715.99Vessel  LM, n (%)0 (0 %)16 (1.6)0.02  LAD, n (%)146 (44.2 %)417(40.9 %)NS  RCX, n (%)72 (21.8 %)234 (22.9 %)NS  RCA, n (%)105 (31.8 %)327 (32.1 %)NS  Graft, n (%)7 (2.3 %)26 (2.5 %)NSLesions  1, n (%)200 (77.8 %)542 (69.4 %)\<0.01  2, n (%)41 (15.8 %)203 (26 %)\<0.01  3, n (%)16 (6.2 %)36 (4.6 %)NS  Final balloon size3.193.55  LVEF \<0,4013 (6.2 %)72 (14.9 %)\<0.01*PCI* percutaneous coronary intervention, *LM* left main coronary artery, *LAD* left anterior descending coronary artery, *RXC* ramus circumflex coronary artery, *RCA* right coronary artery, *LVEF* left ventricular ejection fraction

The 30-day MACCE-free survival is not significantly different between the Venlo and Alkmaar populations. The other endpoints did not occur enough to compare statistically (Table [6](#Tab6){ref-type="table"}).Table 6Thirty-day follow-up at Venlo and AlkmaarEndpointVenlo (*n* = 257)Alkmaar (*n* = 781)PDeath, *n* (%)0 (0.0 %)0 (0.00 %)Re-PCI, target vessel, *n* (%)5 (2.1 %)4 (2.34 %)Re-PCI, non-target vessel, *n* (%)2 (0.8 %)1 (0.58 %)Emergency CABG, *n* (%)0 (0.0 %)0 (0.00 %)Semi-elective CABG, *n* (%)2 (0.8 %)4 (2.34 %)AMI, *n* (%)2 (0.8 %)1 (0.58 %)CVA, *n* (%)1 (0.4 %)1 (0.58 %)Major bleeding, *n* (%)0 (0.0 %)5 (2.92 %)Cath lab MACE, *n* (%)1 (0.4 %)4 (2.34 %)MACCE, *n* (%)10 (3.0 %)20 (11.70 %)NS*PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *AMI* acute myocardial infarction, *CVA* cerebrovascular accident, *MAC(C)E* major adverse cardiovascular (and cerebral) events, *Cath lab* catheterisation laboratory

Discussion {#Sec12}
==========

This study reports the first results of off-site PCI and/or FFR procedures in Venlo. The results show a low occurrence of complications and MACE resulting in a successful early outcome of off-site PCIs.

In the study population 19 (5.7 %) patients suffered from a procedural complication. In the 6-month follow-up a MACE occurred in 43 (13,1 %) patients, mostly re-PCI. Only seven patients died. None of the deaths were directly related to the PCI or FFR procedure. The success rate was high at 94.9 %.

Patients who underwent FFR without subsequent PCI were either proven to have significant 3-vessel disease by FFR evaluation and considered eligible for CABG, or were proven to have no significant vessel disease at all.

For the first stage of off-site PCIs at VieCuri it was decided to perform only elective PCIs. Despite this, 23 primary PCIs were performed in the study period, mostly because the condition of the patients was judged to be too critical for transportation to a tertiary hospital. Two of these patients died within 2 days due to the extent and complications of the acute MI. Around-the-clock intervention of primary PCIs will be introduced in a second stage after which the delay in STEMI patients in our region is expected to be significantly reduced as transportation to a tertiary centre is no longer needed. The goal of 90 % of the patients within 90 min should be achieved when primary PCIs are introduced in the Venlo area \[[@CR25]\].

As all patients scheduled for a PCI with stent placement require a P2Y~12~ inhibitor \[[@CR18]\], analysis of prescribed medication in our study population was performed. In total 94.0 % of the patients received a P2Y~12~ inhibitor. All of the 20 patients not receiving a P2Y~12~ inhibitor only had a FFR measurement performed. There were two reasons why these patients did not receive a P2Y~12~ inhibitor. They were either scheduled for a diagnostic coronary catheterisation during which the interventional cardiologist decided to evaluate a moderate stenosis with FFR, or they were scheduled for CABG and further evaluation of a moderate stenosis was needed.

When comparing the elective PCIs of this study with the elective PCIs of the first off-site PCI centre, Alkmaar, most baseline characteristics and PCI specifications are not significantly different. However, a significant difference is the number of lesions per patient. This can partly be explained by the fact that we compared our first-year data to their second-year data. At the start of the off-site PCIs in Venlo it was decided to perform high-risk procedures at a tertiary hospital. Excluding high-risk patients from treatment at an off-site PCI centre is recommended by the Society for Cardiac Angiography and Interventions \[[@CR9]\]. However, more high-risk procedures could be performed in Venlo as numerous studies have shown acceptable outcomes in high-risk patients \[[@CR12]--[@CR14], [@CR31]\].

The 30-day follow-up in the two study groups does not differ significantly, thus showing the early outcome of off-site PCI at Venlo to be as successful as Alkmaar.

Limitations {#Sec13}
===========

As this is a retrospective study, not all data could be obtained. Also, not all our data could be compared with the study population from Alkmaar as the studies looked into different baseline characteristics and specifications of the PCI procedures. We did not compare our data to an on-site PCI centre.

Conclusion {#Sec14}
==========

This study reports the outcome of the first stage of off-site PCIs and FFR measurements at VieCuri Medical Centre for Northern Limburg in Venlo. It demonstrates that, though in a limited patient group, off-site PCI at VieCuri Venlo has a high success rate. Furthermore it shows a low complication rate, low MACE and no procedure-related mortality.
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